Innovent Biologics, a China-based biopharmaceutical company, announced that its new drug application for its proposed adalimumab biosimilar IBI303, referencing Humira, was accepted by the National Medical Products Administration.
Earlier this week, Innovent Biologics, a China-based biopharmaceutical company, announced that its new drug application for its proposed adalimumab biosimilar IBI303, referencing Humira, was accepted by the National Medical Products Administration (NMPA, formerly known as the China Food and Drug Administration).
The application was accepted based on analytical, clinical, and pharmacokinetic (PK) data generated by 3 clinical studies. Innovent is seeking indications for the treatment of ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Phase 3 comparative efficacy and safety studies were conducted in patients with ankylosing spondylitis. In addition, researchers also analyzed and compared PK parameters and immunogenicity of IBI303 versus reference adalimumab.
“Innovent successfully developed IBI303, which will provide as an alternative to the branded original product. Because of the high price of the branded drug, many patients in China have difficulty getting treatment for these chronic disease[s] which require long-term medication,” said Qinwei Zhou, MD, chief operating officer at Innovent. “We believe IBI303 will become a high-quality biosimilar drug for Chinese patients.”
Michael Yu, the founder, CEO, and chairman of Innovent explained that IBI303 is the second new drug application that the company has submitted to the NMPA. Within its pipeline, Innovent has 2 other potential biosimilars currently undergoing phase 3 clinical trials: IBI301, a proposed biosimilar rituximab, and IBI305, a proposed biosimilar bevacizumab.
“We are excited about reaching this important milestone much quicker than we originally planned. Our team will continue to deliver high-quality biopharmaceutical drug[s] from our rich pipeline to benefit more ordinary people,” said Yu.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).